Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in High-Risk APL
NCT00551460Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2007
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute promyelocytic leukemia (APL), sponsored by SWOG Cancer Research Network. Primary endpoints: Continuous Complete Remission at 3 years and Mortality Rate at 6 weeks. Started Nov 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00551460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551460.